Germany
Manufacturer/ Producer
Since 1888 Meisinger is one of the world's leading developers and manufacturers of high-tech instruments in the field of dental and medical technology. With more than 12, 000 items available, MEISINGER offers a wide range of products for both practice and laboratory – from rotary instruments to special instrument systems for oral implantology. With its Bone Management product line MEISINGER also develops perfectly harmonized system solutions for the controlled optimization of the bony implant site – completely independent of the used implant system. Besides prosthetic aspects, the minimally invasive character of the surgical intervention in complicated indications plays an important role in this product line. In the highly specialized production facility MEISINGER produces proven instruments and innovative products at feasibility limits. Manufacturing tolerances are held to unprecedented levels. The excellent production standard is appreciated around the globe. At the company headquarter in Neuss (Germany), 45 million individual instruments are manufactured and sold every year under the MEISINGER brand through 600 trade partners in more than 100 countries. Founded by Artur Meisinger, the independent family-run company currently has 350 employees and is managed by the fourth generation and managing partners Dr. Burkard Höchst and Sebastian Voss.
Manufacturer/ Producer
Hansemannstr. 10
41468 Neuss - Germany
Switzerland
Novostia, a Swiss startup founded in 2017, has entrusted MPS with the manufacture of its TRIFLO artificial valve, a revolutionary aortic prosthesis on several levels. Thanks to its aerodynamic design, the presence of three leaflets and the absence of physical pivot axes for the leaflets, the TRIFLO valve aims to satisfy the following three criteria: - A device lifespan at least equal to that of the patient, to avoid the need for a second surgical procedure. This means more than 30 million flap openings and closures per year, with no leaks, blockages, cracks, ruptures or flap escapes. - The artificial valve must not lead to thrombosis, so that patients do not need to take anticoagulants. - Operation (flap opening and closing, blood flow through the valve) must be as silent as possible, so as not to disturb the patient or those around him, day or night. The TRIFLO device is in clinical trial and is not approved for sale.
Request for a quoteCreate one request and get multiple quotes form verified suppliers.